GZMB and myeloid sarcoma: Higher levels of natural granzyme B antagonist serpina3N were found in the CSF of MS patients, particularly in the progressive forms, and were correlated with neurofilament levels, suggesting that CNS cells attempt but do not succeed to prevent granzyme B toxicity in MS (88).